Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
Novo Nordisk Belgium Manufacturing Holding SA from Brussel, company number BE0455204073, closed financial year 2025 with a result of € -45.7 million after tax. Compared with financial year 2024, the result moved from € 689,192 to € -45.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ 81.6 million
▼ 36% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -45.7 million
▼ still € 689,192 profit in 2024
Profit after tax over the fiscal year.
€ 234,848
▲ € 216,378 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -134.4 million.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 258,224
▲ 3% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Profit after taxes | € -110,255,770 | € 421,288 | € 689,192 | € -45,687,844 | ▼ € 46.4 million |
| Equity | € 126,172,447 | € 126,593,734 | € 127,282,927 | € 81,595,082 | ▼ 36% |
| Total debts | € 90,734 | € 153,359 | € 351,446 | € 258,224 | ▼ 27% |
| Cash | € 122,456 | € 19,274,689 | € 18,471 | € 234,848 | ▲ € 216,378 |
| Retained profit | € -89,863,656 | € -89,442,369 | € -88,753,176 | € -134,441,021 | ▼ € 45.7 million |
| Balance sheet total | € 126,263,181 | € 126,747,093 | € 127,634,373 | € 81,853,306 | ▼ 36% |
Key figures of Novo Nordisk Belgium Manufacturing Holding SA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Novo Nordisk Belgium Manufacturing Holding SA?
What happened at Novo Nordisk Belgium Manufacturing Holding SA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- John KUCKELMAN stepped down as director. NBB
- Erik, Lorin RASMUSSEN stepped down as director. NBB
- Cengic DZENANA stepped down as director. NBB
- Andrew FINNEGAN stepped down as director. NBB
- Geoffroy BECKERS stepped down as director. NBB
- Sabine CARLINO stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 45.7 million (▼ € 46.4 million vs 2024). Source: NBB ↗
- Bruno STUTZMANN stepped down as director. NBB
In short
From € 110.3 million loss in 2022 to € 45.7 million loss in 2025.
Paid € 818,003 in corporate taxes since 2022.
Best year ever: 2024, with € 689,192 profit.
A new publication or filing at Novo Nordisk Belgium Manufacturing Holding SA? We notify you, reason included.
Follow Novo Nordisk Belgium Manufacturing Holding SADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Novo Nordisk A/S (100%). It owns Novo Nordisk Production Belgium SA itself.
Directors
According to the 2025 annual accounts
since 2023 · until 2024
since 2024 · until 2031
since 2024 · until 2031
Cengic DZENANA
Managing director
since 2025 · until 2031
since 2024 · until 2031
Geoffroy BECKERS
Managing director
Also active at: Novo Nordisk Production Belgium SA, AM Biologics Filling Brussels
since 2025 · until 2031
since 2025 · until 2031
since 2024 · until 2025
Shareholders
Novo Nordisk A/S
100%
Participations
Establishments
Establishment units
Physical locations of this company
Sint Lendriksborre 10
1120 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0455.204.073
- VAT number
- BE 0455.204.073
- Registered office
- Sint Lendriksborre 10, 1120 Brussel
- Names & denominations
- Novo Nordisk Belgium Manufacturing Holding SA
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 28 April 1995
- Peppol
- Not registered